DR-70^(TM)检测在消化系统肿瘤中的应用  

Clinical application of the AMDL DR-70^(TM) immunoassay kit for the digestive system tumors.

作　　者：吴群[1] 吴东方[2] 谢文[2] 余小萍[2] 江桥[2] 

机构地区：[1]武汉大学医学院微生物学及免疫学教研室,武汉430071 [2]武汉大学中南医院检验科,武汉430071

出　　处：《上海医学检验杂志》2001年第6期346-347,共2页Shanghai Journal of Medical Laboratory Sciences

摘　　要：目的评价 DR- 70 TM在消化系肿瘤筛查中的价值。方法应用 EL ISA对 135例确诊为食道癌、胃癌、肠癌或肝癌的患者和 16 6例年龄相当的健康者进行了对照检测。结果以 5 .3mg/ L 为临界值 ,食道癌阳性率为92 .9%,胃癌阳性率为 92 .9%,肠癌阳性率为 83.3%,肝癌阳性率为 83.8%,合计总阳性率为 85 .8%;与健康对照组结果比较 ,P<0 .0 0 1,差异呈高度显著性。结论 DR- 70Objective To evaluate the clinical value of DR 70 TM in digestive system tumors. Method A clinical study using DR 70 TM enzyme linked immunosorbent assay (ELISA) in 135 patients with digestive system tumors, including esophageal carcinoma, gastric cancer, cancers of colon and rectum, hepatic cancer and 166 healthy subjects. Results The positive rates of DR 70 TM were 92 85%,92 85%,83 33%,83 78% for esophageal carcinoma, gastric cancer, cancers of colon and rectum, hepatic cancer respectively. There was very significant difference between the patient group and control (P<0 001). Conclusion The DR 70 TM assay may be useful in clinical study of the digestive system cancers.

关 键 词：DR-70^TM 食道癌 胃癌 肠癌 肝癌 消化系肿瘤 

分 类 号：R735[医药卫生—肿瘤] R730.45[医药卫生—临床医学]